New Blood Test Predicts Alzheimer's Decline in Landmark Trial Data

ST. LOUIS, MO – March 19, 2026

A novel blood test is showing remarkable potential to predict the speed of cognitive and functional decline in people with early Alzheimer’s disease, according to new data presented this week. The findings, unveiled at the prestigious AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference, stem from the analysis of C2N Diagnostics' eMTBR-tau243 plasma assay within the large-scale Evoke and Evoke+ Phase 3 clinical trials. This development marks a significant step forward in the quest for non-invasive tools that can provide a clearer picture of an individual's disease trajectory, paving the way for more personalized treatment strategies.

The Science of Prediction: Beyond Amyloid to Tau

For decades, the scientific narrative around Alzheimer's disease has been dominated by amyloid-beta, the protein that forms plaques in the brain. However, a growing body of evidence highlights the critical role of another protein: tau. When tau becomes abnormal, it forms tangles inside brain cells, a development that correlates much more closely with the actual symptoms of memory loss and cognitive decline. The latest generation of diagnostic tools is now able to distinguish between these different pathologies using a simple blood draw.

The data presented from the Evoke trials demonstrated that two distinct blood biomarkers provide complementary, rather than redundant, information. The first, p-tau217, is widely recognized as an early indicator of amyloid plaque pathology. The second is C2N's eMTBR-tau243, which measures a specific fragment of the tau protein directly associated with the formation of neurofibrillary tangles. The analysis showed that baseline levels of both biomarkers independently predicted future cognitive and functional decline. When used together, they offer a more powerful and nuanced method for biologically staging the disease, helping to identify which patients are on a faster track of progression.

A New Layer of Insight from the Evoke Trials

The data emerged from the Evoke and Evoke+ studies, a pair of major Phase 3 trials sponsored by Novo Nordisk to investigate the effects of oral semaglutide on early Alzheimer's disease. While the trials ultimately did not meet their primary endpoints for clinical efficacy, their comprehensive design included the collection of extensive biomarker data from thousands of participants. This has created a rich scientific dataset that is now yielding crucial insights into the underlying biology of the disease, independent of the drug's outcome.

C2N's eMTBR-tau243 assay, currently designated for "Research Use Only," was a key part of this deep-dive analysis. Its inclusion in a trial of this scale provides significant validation for the biomarker's utility. "The inclusion of eMTBR-tau243 in Evoke/Evoke+ analyses reflects the growing interest in looking at tau biology in ways that may better predict which patients with early symptomatic Alzheimer’s disease will progress more quickly than others," said Dr. Joel Braunstein, CEO and President of C2N Diagnostics, in a statement. "This information may be instrumental for future precision medicine strategies in novel treatment development and patient care."

The Race for a Better Alzheimer's Blood Test

The announcement places C2N Diagnostics at a pivotal juncture in the highly competitive and rapidly expanding market for Alzheimer's diagnostics, which is projected to surpass $20 billion globally by the early 2030s. The field is racing to move beyond expensive PET scans and invasive cerebrospinal fluid (CSF) tests to accessible, scalable blood-based biomarkers.

Several major players are already in the market. Roche, for instance, has received FDA clearance for its Elecsys pTau181 blood test, while Quest Diagnostics offers a suite of laboratory-developed tests. However, C2N's assay targets a different piece of the puzzle. While many existing tests focus on early amyloid pathology, eMTBR-tau243 is designed to specifically measure tangle pathology, offering a prognostic tool to gauge the severity and speed of progression. This differentiation could give the company a crucial edge, particularly in monitoring patients in later stages or assessing the effectiveness of emerging anti-tau therapies. The company is already building on this with its PrecivityTauDx™ program, signaling a clear intent to transition its research tools into the clinical arena.

Paving the Way for Precision Medicine

Perhaps the most profound implication of this new data is its contribution to the era of precision medicine for Alzheimer's. The disease is notoriously heterogeneous, with progression rates and underlying pathologies varying significantly from person to person. A one-size-fits-all treatment approach has proven largely ineffective. Advanced biomarkers like eMTBR-tau243 are essential for dissecting this complexity.

By providing a more accurate prognosis, the assay could help clinicians and families better plan for future care. More importantly, it could revolutionize clinical trials and treatment selection. For example, a patient with high levels of the eMTBR-tau243 biomarker might be an ideal candidate for a trial testing an anti-tau drug. Conversely, a patient with high p-tau217 but low eMTBR-tau243 might respond better to an anti-amyloid therapy. Experts in the field believe this combined approach is the future. According to one leading researcher not affiliated with the company, while one biomarker will likely be used for initial screening, a complementary one that tracks tau tangles will be invaluable for refining prognosis and confirming a more advanced disease state.

The findings from the Evoke/Evoke+ analyses represent more than just the validation of a single test. They underscore a fundamental shift in understanding Alzheimer's, moving towards a multi-faceted diagnostic panel that can capture the unique biological signature of each patient's disease. This holistic view is the foundation upon which truly personalized and effective treatments will be built.